Generic Name and Formulations:
Desloratadine 5mg; tabs.
Merck & Co., Inc.
Indications for CLARINEX:
Seasonal allergic rhinitis (for patients ≥2yrs old). Perennial allergic rhinitis, chronic idiopathic urticaria (for patients ≥6 months old).
5mg once daily. Renal or hepatic impairment: initially 5mg every other day.
Use other forms.
ODT: Phenylketonurics. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pharyngitis, dry mouth or throat, myalgia, fatigue, somnolence, dysmenorrhea, headache, nausea, dizziness. Children: fever, diarrhea, upper respiratory infections, irritability, coughing.
Formerly known under the brand name Clarinex ODT.
Tabs (YES); syrup (NO)
Tabs—100, 500; Syrup—4oz, 16oz; ODT—contact supplier
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics